WO2022152144A9 - 结合cd73的蛋白及其应用 - Google Patents

结合cd73的蛋白及其应用 Download PDF

Info

Publication number
WO2022152144A9
WO2022152144A9 PCT/CN2022/071520 CN2022071520W WO2022152144A9 WO 2022152144 A9 WO2022152144 A9 WO 2022152144A9 CN 2022071520 W CN2022071520 W CN 2022071520W WO 2022152144 A9 WO2022152144 A9 WO 2022152144A9
Authority
WO
WIPO (PCT)
Prior art keywords
binding protein
isolated antigen
region
cdr
seq
Prior art date
Application number
PCT/CN2022/071520
Other languages
English (en)
French (fr)
Other versions
WO2022152144A1 (zh
Inventor
徐锦根
朱向阳
于海佳
韦小越
瞿丽丽
任晓琛
Original Assignee
上海华奥泰生物药业股份有限公司
华博生物医药技术（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海华奥泰生物药业股份有限公司, 华博生物医药技术（上海）有限公司 filed Critical 上海华奥泰生物药业股份有限公司
Priority to JP2023538013A priority Critical patent/JP2024502758A/ja
Priority to CN202280007942.5A priority patent/CN116568811A/zh
Priority to AU2022207557A priority patent/AU2022207557A1/en
Priority to US18/270,400 priority patent/US20240067747A1/en
Priority to KR1020237027249A priority patent/KR20230132511A/ko
Priority to EP22739022.6A priority patent/EP4279507A1/en
Publication of WO2022152144A1 publication Critical patent/WO2022152144A1/zh
Publication of WO2022152144A9 publication Critical patent/WO2022152144A9/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供一种分离的抗原结合蛋白，其能够特异性结合CD73，所述抗原结合蛋白包含重链可变区VH中的至少一个CDR，所述VH包含SEQ ID NO:49所示的氨基酸序列；还提供了所述分离的抗原结合蛋白的制备方法及应用。
PCT/CN2022/071520 2021-01-13 2022-01-12 结合cd73的蛋白及其应用 WO2022152144A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2023538013A JP2024502758A (ja) 2021-01-13 2022-01-12 Ｃｄ７３結合タンパク質及びその使用
CN202280007942.5A CN116568811A (zh) 2021-01-13 2022-01-12 结合cd73的蛋白及其应用
AU2022207557A AU2022207557A1 (en) 2021-01-13 2022-01-12 Cd73-binding protein and use thereof
US18/270,400 US20240067747A1 (en) 2021-01-13 2022-01-12 Cd73-binding protein and use thereof
KR1020237027249A KR20230132511A (ko) 2021-01-13 2022-01-12 Cd73에 결합하는 단백질 및 이의 용도
EP22739022.6A EP4279507A1 (en) 2021-01-13 2022-01-12 Cd73-binding protein and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110045071.3 2021-01-13
CN202110045071 2021-01-13

Publications (2)

Publication Number Publication Date
WO2022152144A1 WO2022152144A1 (zh) 2022-07-21
WO2022152144A9 true WO2022152144A9 (zh) 2022-09-09

Family

ID=82447969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/071520 WO2022152144A1 (zh) 2021-01-13 2022-01-12 结合cd73的蛋白及其应用

Country Status (7)

Country Link
US (1) US20240067747A1 (zh)
EP (1) EP4279507A1 (zh)
JP (1) JP2024502758A (zh)
KR (1) KR20230132511A (zh)
CN (1) CN116568811A (zh)
AU (1) AU2022207557A1 (zh)
WO (1) WO2022152144A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202405018A (zh) * 2022-06-08 2024-02-01 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３抗體雞尾酒療法
TW202409092A (zh) * 2022-06-08 2024-03-01 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ３９／ｃｄ７３雙特異性抗原結合蛋白及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
EP3554515A4 (en) * 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
US11787858B2 (en) * 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用

Also Published As

Publication number Publication date
AU2022207557A9 (en) 2024-05-30
EP4279507A1 (en) 2023-11-22
WO2022152144A1 (zh) 2022-07-21
JP2024502758A (ja) 2024-01-23
US20240067747A1 (en) 2024-02-29
KR20230132511A (ko) 2023-09-15
AU2022207557A1 (en) 2023-07-06
CN116568811A (zh) 2023-08-08

Similar Documents

Publication Publication Date Title
WO2022152144A9 (zh) 结合cd73的蛋白及其应用
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
NZ715896A (en) Humanized or chimeric cd3 antibodies
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
RS53157B (en) SCLEROSTINE ANTIBODIES
NZ605980A (en) Anti-fap antibodies and methods of use
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
NZ592151A (en) Anti-igf antibodies
WO2006050949A3 (de) Superagonistische anti-cd28 antikörper
WO2009004066A3 (en) Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
SI2731973T1 (en) A bacterial host strain expressing a recombinant DSBC
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
ZA202211457B (en) Anti-cd73 antibody and use thereof
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
NZ610091A (en) Antibodies
HRP20231175T1 (hr) Postupci kultiviranja stanica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22739022

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280007942.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023538013

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 18270400

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2022207557

Country of ref document: AU

Date of ref document: 20220112

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20237027249

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020237027249

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022739022

Country of ref document: EP

Effective date: 20230814